oral or topical composition and use of a factor 2-related erythroid nuclear factor 2 agonist and a hepatic receptor x agonist as active agents in an oral or topical composition to benefit hair fiber growth and / or induce the antioxidant response element (are)
GAIL JENKINS,LINDA JANE WAINWRIGHT,MAGDALENA SAWICKA,RANJIT KAUR BHOGAL
申请号：
BR112017012648
公开号：
BR112017012648A2
申请日:
2015.12.04
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
An oral or topical composition comprising a factor 2 related erythroid nuclear factor 2 agonist and a hepatic receptor x agonist is disclosed, wherein the amounts of each of the factor 2 related erythroid nuclear factor 2 agonist and the receptor agonist are each. hepatic x produce a synergistic benefit of hair fiber growth, wherein the oral or topical composition comprises = 9, preferably = 8% by weight of beta-sitosterol, wherein when the oral or topical composition comprises a catechin, the oral or The topical composition comprises 0.001 to 90, preferably 0.005 to 70, more preferably 0.01 to 50% by weight of catechins, wherein the oral or topical composition excludes pregnenolone, 4,5-dihydrofuranodien-6-one, epoxy santamarine, hydroquinone, longistiline. , monacoline k, protoanemonine, n- (2,2,2-trifluorethyl) -N- [4- (2,2,2-trifluor-1-hydroxy-1-trifluoromethyl ethyl) phenyl] - benzenesulfonamide, dihydronepetalactone, iridomirmecin and dihydroacti nidiolide, wherein when the oral or topical composition comprises gugulsterone and epigallocatechin gallate, the oral or topical composition excludes a weight ratio of gugulsterone to epigalocatechin gallate from 1 to 28, and wherein when the oral or topical composition comprises dilauramide glutamide sodium lysine, the oral or topical composition excludes 0.3% by weight of dilauramide glutamide sodium lysine.é revelada uma composição oral ou tópica que compreende um agonista do fator nuclear eritróide 2 relacionado ao fator 2 e um agonista do receptor hepático x, em que as quantidades de cada do agonista do fator nuclear eritróide 2 relacionado ao fator 2 e do agonista do receptor hepático x produzem um benefício sinérgico de crescimento da fibra capilar, em que a composição oral ou tópica compreende = 9, preferivelmente = 8% em peso de beta-sitosterol, em que quando a composição oral ou tópica compreende uma catequina, a composição oral ou tópica compreende 0,001 a 90, preferivelmente 0,005 a 70, mais preferivelment
